The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes
Open accessAbstract
OBJECTIVE—In patients with type 2 diabetes, exenatide reduces A1C, postprandial and fasting glucose, and weight. In this study we investigated the effects of continuous exenatide administration from a long-acting release (LAR) formulation. RESEARCH DESIGN AND METHODS—In this randomized, placebo-controlled phase 2 study, exenatide LAR (0.8 or 2.0 mg) was administered subcutaneously once weekly for 15 weeks to subjects with type 2 diabetes (n = 45) suboptimally controlled with metformin (60%) and/or diet and exercise (40%): 40% female, A1C (mean ± SD) 8.5 ± 1.2%, fasting plasma glucose 9.9 ± 2.3 mmol/l, weight 106 ± 20 kg, and diabetes duration 5 ± 4 years. RESULTS—From baseline to week 15, exenatide LAR reduced mean ± SE A1C by −1.4 ± 0.3% (0.8 mg) and −1.7 ± 0.3% (2.0 mg), compared with +0.4 ± 0.3% with placebo LAR (P < 0.0001 for both). A1C of ≤7% was achieved by 36 and 86% of subjects receiving 0.8 and 2.0 mg exenatide LAR, respectively, compared with 0% of subjects receiving placebo LAR. Fasting plasma glucose was reduced by −2.4 ± 0.9 mmol/l (0.8 mg) and −2.2 ± 0.5 mmol/l (2.0 mg) compared with +1.0 ± 0.7 mmol/l with placebo LAR (P < 0.001 for both). Exenatide LAR reduced self-monitored postprandial hyperglycemia. Subjects receiving 2.0 mg exenatide LAR had body weight reductions (−3.8 ± 1.4 kg) (P < 0.05), whereas body weight was unchanged with both placebo LAR and the 0.8-mg dose. Mild nausea was the most frequent adverse event. No subjects treated with exenatide LAR withdrew from the study. CONCLUSIONS—Exenatide LAR offers the potential of 24-h glycemic control and weight reduction with a novel once-weekly treatment for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
(1997) · JAMA · doi:10.1001/jama.277.11.925 · Cited by 668
Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationPancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Self-citationManagement of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Central Control of Body Weight and Appetite
Woods, S. C., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 458
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Self-citationA Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Buse, J. B., Drucker, D. J., Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., Porter, L. E., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1914 · Cited by 356
Self-citationLong-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Glaesner, W., Mark Vick, A., Millican, R., Ellis, B., Tschang, S., Tian, Y., Bokvist, K., Brenner, M., Koester, A., Porksen, N., et al. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1080 · Cited by 305
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Peptidomimetic therapeutics: scientific approaches and opportunities
Qvit, N., Rubin, S. J. S., Urban, T. J., Mochly-Rosen, D., & Gross, E. R. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.003 · Cited by 273
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
Role of Metformin for Weight Management in Patients Without Type 2 Diabetes
Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111
Morano, S., Romagnoli, E., Filardi, T., Nieddu, L., Mandosi, E., Fallarino, M., Turinese, I., Dagostino, M. P., Lenzi, A., & Carnevale, V. (2015) · Acta Diabetologica · doi:10.1007/s00592-014-0710-z · Cited by 110
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
Cheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Sun, F., Yu, K., Yang, Z., Wu, S., Zhang, Y., Shi, L., Ji, L., & Zhan, S. (2012) · Experimental Diabetes Research · doi:10.1155/2012/230624 · Cited by 58
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Samson, S. L., Gonzalez, E. V., Yechoor, V., Bajaj, M., Oka, K., & Chan, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.198 · Cited by 54
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Self-citationClinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
López-Ruiz, A., Peso-Gilsanz, C., Meoro-Avilés, A., Soriano-Palao, J., Andreu, A., Cabezuelo, J., & Arias, J. L. (2010) · Pharmacy World & Science · doi:10.1007/s11096-010-9423-8 · Cited by 44
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Yang, G.-R., Zhao, X.-L., Jin, F., Shi, L.-H., & Yang, J.-K. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.386 · Cited by 29
Stonehouse, A., Walsh, B., & Cuddihy, R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0076 · Cited by 26
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Metadata
- Authors
- Kim, D., MacConell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., & Taylor, K.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 30
- Issue
- 6
- Pages
- 1487-1493
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2164416879
- Cited by
- 446
- References
- 28
- FWCI
- 40.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.